Clovis Oncology, Inc. (NASDAQ:CLVS) belonging to the Medical sector has surged 0.31% and closed its last trading session at $32.68.
The company is expected to report its next EPS on Nov 03 AMC. Currently, the stock has a 1 Year Price Target of $35.43.
The consensus recommendation, according to Zacks Investment research, is 2.43. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 2 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2 and 2.33 respectively.
Clovis Oncology, Inc. on 9/30/2016 reported its EPS as $-3.37 with the analysts projecting the EPS of the stock as $-2.1. The company beat the analyst EPS Estimate with the difference of $-1.27. This shows a surprise factor of -60.5%.
Many analysts have provided their estimated foresights on Clovis Oncology, Inc. Earnings, with 8 analysts believing the company would generate an Average Estimate of $-1.95. Whereas they predicted High and Low Earnings Estimate as $-1.62 and $-2.25 respectively. While in the same Quarter Previous year, the Actual EPS was $-2.62.
The Company got Upgrade by Credit Suisse on 21-Sep-16 from Neutral to Outperform.
Insider Trades for Clovis Oncology, Inc. show that the latest trade was made on 1 Nov 2015 where Mast (Erle T), the Chief Financial Officer completed a transaction type “Sell” in which 500 shares were traded at a price of $104.28.
12 Insider Sales transactions were made totaling 37733 shares traded.
7 analysts projected Price Targets for Clovis Oncology, Inc.. The analysts believe that the company stock price could grow as high as $50. The Low Price target projection by analysts is $12 and the Mean Price Target is $35.43.
Clovis Oncology, Inc. (NASDAQ:CLVS) has the market capitalization of $1.53 Billion. The company rocked its 52-Week High of $109.18 on Nov 2, 2015 and touched its 52-Week Low of $11.57 on Jun 27, 2016. The stock has Return on Assets (ROA) of -63.4 percent. Return on Equity (ROE) stands at -162.5% and Return on Investment (ROI) of 0 percent.
The stock is currently showing YTD performance of -6.63 Percent. The company has Beta Value of 1.89 and ATR value of 3. The Weekly and Monthly Volatility stands at 11.96% and 9.05%.
Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations. Clovis Oncology Inc. is headquartered in Colorado, USA.